培美曲塞联合卡铂二线治疗晚期非小细胞肺癌的疗效及安全性分析  

Efficacy and Security Analysis of Pemetrexed Combined with Carboplatin as the Second-line Treatment for Advanced Non-small Cell Lung Cancer

作　　者：高羽[1] 朱晓敏[1] 孔繁丽[1] 潘鑫焱[1] 杜敏[1] 李志民[1] 

机构地区：[1]大连医科大学附属中心医院,辽宁大连116033

出　　处：《中国医学创新》2016年第7期4-6,共3页Medical Innovation of China

基　　金：大连市卫生和计划生育委员会科技项目(大卫科发[2014]142号)

摘　　要：目的:分析研究培美曲塞联合卡铂二线化疗治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:选取本院2013年1月-2015年9月收治的100例晚期NSCLC患者作为研究对象,应用培美曲塞联合卡铂治疗50例,培美曲塞单药治疗50例,评价两种治疗疗效及不良反应。结果:培美曲塞联合卡铂组有效率及临床获益率均高于培美曲塞组,比较差异有统计学意义(P<0.05);两组骨髓抑制发生率及胃肠道反应发生率比较,差异均无统计学意义(P>0.05)。结论:临床上培美曲塞联合卡铂化疗方案能够明显提高晚期NSCLC化疗效果,不良反应少,有较好的耐受性。Objective：To analyze and research the efficacy and security of Pemetrexed combined with Carboplatin as the second-line therapy in the treatment of advanced non-small cell lung cancer（NSCLC）.Method：100 patients with advanced NSCLC in our hospital from January 2013 to September 2015 were selected as the research objects.50 patients received Pemetrexed and Carboplatin for treatment and the rest 50 patients received Pemetrexed.The efficacy and adverse effects of the two treatment methods were compared.Result：The effective rate and clinical benefit rate of the Pemetrexed combined with Carboplatin group were higher than those of the Pemetrexed group,the differences were statistically significant（P〈0.05）.The differences in the incidence rates of myelosuppression and gastrointestinal reaction between the two groups were not statistically significant（P〈0.05）.Conclusion：The clinical efficacy of Pemetrexed combined with Carboplatin in the treatment of advanced NSCLC is remarkable,it has fewer adverse reactions and better tolerance.

关 键 词：培美曲塞 卡铂 非小细胞肺癌 化疗 

分 类 号：R734.2[医药卫生—肿瘤]